DEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS

Transcription

1 DEVELOPING PRECISION THERAPIES IN HAEMATOLOGIC CANCERS DNB HEALTHCARE CONFERENCE DECEMBER 14 TH, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway IR contact:

2 Disclaimer This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector s business, financial condition and results of operations. The terms anticipates, assumes, believes, can, could, estimates, expects, forecasts, intends, may, might, plans, should, projects, will, would or, in each case, their negative, or other variations or comparable terminology are used to identify forwardlooking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin, technology changes and new products in Nordic Nanovector s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 2

3 Nordic Nanovector at a glance Focused on the development of precision therapies for haematological cancers Leveraging proprietary Antibody Radionuclide Conjugate (ARC) technology to build a pipeline of candidates Pipeline led by Betalutin for treating non-hodgkin s lymphoma (NHL) Novel anti-cd37 ARC in Phase 2b pivotal clinical trial - PARADIGME Promising efficacy with sustainable duration of response, favourable safety profile Clear plan to bring Betalutin to market Designed to enhance Betalutin s chances of gaining regulatory approval with a competitive product profile Intend to independently commercialize Betalutin in major markets Deep pipeline of targeted therapies for haematological cancers Listed on the Oslo Stock Exchange (OSE: NANO) 3

4 Advancing a promising pipeline of targeted therapies for haematological cancers Product Targeted indication Discovery Preclinical Phase 1 Phase 2 Phase 3 BETALUTIN currently targeted indications BETALUTIN LCM indications FL, 3 rd line FL, 2 nd line, combination with rituximab R/R DLBCL, SCT ineligible R/R DLBCL, conditioning Other NHL subtypes HUMALUTIN * NHL, 1 st line Chimeric lilotomab with novel payloads (ARCs, ADCs) Leukaemia, multiple partnered projects AFFILUTIN Multiple myeloma * Chimeric anti-cd37 ARC LCM: Life Cycle Management 4

5 Follicular Lymphoma (FL) a subset of NHL, representing a large unmet medical need with no cure 1 st line 2 nd line 3 rd line Later lines Approx patients Approx patients Approx patients Approx patients Anti-CD20 (Rituximab, obinutuzumab) + + Chemotherapy (Bendamustine, CHOP, CVP) Followed by: Rituximab maintenance Radioimmunotherapy + Anti-CD20 (Rituximab, obinutuzumab) Chemotherapy (Bendamustine, fludarabine, CHOP) OR Anti-CD20 (Rituximab, obinutuzumab) Immunomodulatory agents (Lenalidomide) Idelalisib (Mono) OR Copanlisib (Mono) OR Rituximab (Mono) OR Clinical trials with novel drugs (CAR-T) BSC / Palliative therapy OR Radioimmunotherapy Radioimmunotherapy Followed by: High dose chemo + Stem Cell Transplant Allogenic SCT Rituximab / obinutuzumab maintenance + OR Rituximab Lenalidomide Treatment regimens including listed options are either approved or recommended by NCCN or ESMO guidelines 5 Remission Remission Remission Remission Relapse Relapse Relapse Relapse Remission

6 Betalutin is a novel anti-cd37 ARC specifically designed to treat NHL DESIGN PROPERTY DIFFERENTIATION CD37 a validated target for B-cell NHL Highly expressed on B-cells Antibody internalization anchors the payload to cancer cells, resulting in prolonged irradiation of the nucleus A target ideally suited to be effective for patients previously treated with CD20-based therapies. Refractory patients, in particular, represent a major unmet need. Lutetium-177 ideal radionuclide Beta-emitting radionuclide with half-life (6.7 days) matching the circulation time of the antibody A mean penetration depth of 0.23mm Payload properties are well suited for treating NHL while limiting unnecessary side effects Influential nuclear medicine specialists view Lutetium-177 as an advanced radionuclide Multi-cell kill approach Localised tumour cell kill (40-cell radius) from irreparable double strand DNA breaks Cytotoxic effect on poorly perfused or nonantigen expressing cells Expected to deliver better treatment outcomes from a single administration than anti-cd20 therapies and chemotherapy (single cell kill) Lilotomab pre-dosing Optimises Betalutin binding to CD37 on NHL cells Binds CD37 on B-cells and blocks Betalutin binding minimises side effects Enhances attractiveness of CD37 as target for new NHL therapy 6

7 Ready to advance investigation with PARADIGME, a Phase 2b pivotal study in relapsed/refractory FL ARM 1 10MBq/kg 10MBq/kg (- llo + R0) (+ 40mg llo) N = 1 N = 3 PHASE 1 ARM 2 ARM 4 LYMRIT MBq/kg (+ 40mg llo) N = 3 15MBq/kg (- llo) N = 2 ARM 3 15MBq/kg (+ 40mg llo) N = 6 10MBq/kg (- llo) N = 1 15MBq/kg (- llo + R0) N = 3 20MBq/kg 15MBq/kg (+ 100mg/m 2 llo) (+ 100mg/m 2 llo) N = 7 N = 3 PHASE 2 15MBq/kg (+ 40mg llo) N = 30 Discontinued Discontinued 20MBq/kg (+ 100mg/m 2 llo) N <15 PARADIGME Randomisation 15MBq/kg (+ llo 40mg) N = 65 20MBq/kg (+ 100mg/m 2 llo) N = 65 Seamless design approach Aligned with regulatory authority feedback Submitted to regulatory authorities MBq: Megabecquerel; llo: lilotomab; R0: rituximab predosing on day 0; Completed step (all patients enrolled). 7

8 Population of primarily elderly, heavily pre-treated patients with advanced stage disease Median age, years (range) 65, n (%) Male Female Ann Arbor stage at diagnosis*** I/II III/IV Unknown Prior regimens, median (range) 2 prior regimens 2 prior rituximab regimens Prior alkylating agent All Patients (n=64) 69 (40-88) 44 (69%) 35 (55%) 29 (45%) 5 (15%) 23 (68%) 6 (18%) 3 (1-8) 44 (69%) 36 (56%) 52 (81%) FL* (n=49) 69 (40-80) 33 (67%) 27 (55%) 22 (45%) 5 (22%) 15 (65%) 3 (13%) 2 (1-8) 34 (69%) 28 (57%) 38 (78%) Other** (n=15) 68 (57-88) 12 (80%) 8 (53%) 7 (47%) 0 (0%) 7 (64%) 4 (36%) 3 (1-7) 10 (67%) 8 (53%) 14 (93%) Bulky disease >5 cm, n (%) 25 (39%) 22 (45%) 3 (20%) WHO performance status 0/1 40/24 34/15 6/9 This population represents the area of highest unmet medical need and is the target population for Betalutin 8 Kolstad A, et al. Poster presented at ASH Abstract 2769.

9 Single-agent Betalutin is highly active in FL patients, especially in 3L Response rates by subgroup and treatment arm ORR (CR + PR) CR All patients (n=62) 60% 24% All FL patients (n=47) 64% 23% Arm 1 (40/15) (n=25) 68% 28% Arm 4 (100/20) (n=8) 50% 25% Median duration of response Median DoR All inhl patients 13.3m inhl CR patients 20.5m All FL patients with 40/ m FL with 2 prior therapies (3L FL) (n=32) 66% 25% Fl CR patients with 40/ m Results confirm that single-agent Betalutin is highly active in FL patients, especially in 3L Patients with CR remain disease free for a median of over 20.0 months with a one time Betalutin administration 9 Kolstad A, et al. Poster presented at ASH Abstract 2769.

10 Betalutin is well-tolerated, with a manageable safety profile Grade 3/4 TEAEs in 2 patients (n=64) Adverse Event n (%) 2 Neutropenia 1 35 (55%) Thrombocytopenia 1 32 (50%) Leukopenia 1 32 (50%) Lymphopenia 1 22 (34%) Infections Urinary tract infection (1) Sepsis/neutropenic sepsis (2) Pharyngitis (1) Pneumonia (1) 5 (8%) Lymphoma progression 3 (5%) Serious Adverse Event (SAE) Thrombocytopenia 2 (3%) Atrial fibrillation 2 (3%) Lymphoma progression 2 (3%) Overall, Betalutin was well-tolerated, in particular considering the age of enrolled patients Most common grade 3/4 TEAEs are predictable and reversible thrombocytopenia and neutropenia Low incidence of G3/4 infections (<10%) 1. Including events reported as investigations. 2. Two patients had not had hematologic recovery at the time of data cut-off. 10 Kolstad A, et al. Poster presented at ASH Abstract 2769.

11 2 nd Line 3 rd Line Betalutin as a single dose holds significant edge over existing and upcoming competitors in R/R FL CR ORR mdor (months) mpfs (months) mos (months) Source Betalutin (Phase 1/2) 25%* 66%* 13.3m (20.5m in CR patients)* *Kolstad et al, ASH 2017 (32 3L FL pts. as regards CR/ORR, 37 pts. as regards mdor, 15 pts. as regards mdor in CR pts.) Copanlisib (Filed/Phase 2) 16% 58% 12.2m 11.3m Dreyling et al., ASH 2017 (104 patients) Duvelisib 1 (Phase 2) 0% 41% Verastem Pharma, 2016 (83 patients) CTL019 2 (Phase 2) 50% 79% 15m 83% 15m ~65% -- Novartis, ASH 2016 (14 patients) Ibrutinib (Phase 2) Idelalisib (Launched) Nivolumab (Phase 1) MOR208 (Phase 2) Rituximab (Launched) Ibritumomab tiuxetan (Launched) 6% 11% 21% 8% 10% 11% 15% 29% 40% 48% 54% 1 11 No longer in clinical development for FL All agents are approved based on different phase results as mentioned along with asset 2 CAR-T Results from different trials for comparison purpose only and NOT head to head studies 74% ~19.4m >12.5m -- ~20.3m >16m 12m >40% ~13m -- ~6.5m ~7m -- Gopal et al, 2016 (110 patients) Gopal et al, 2014 (125 patients) Lesokhin et al, 2016 (10 patients) Jurczak et al, 2016 (45 patients) McLaughlin et al, 1998 (166 patients) Witzig et al, 2002 (57 patients)

12 Betalutin has a unique value proposition in inhl based on important differentiating factors Alternative target and innovative radionuclide High and durable response Alternative target (CD37) ideal for patients who progress after rituximab (anti-cd20)-based regimens Lutetium-177, preferred by influential NMs, has payload properties that are well suited for treating NHL while limiting unnecessary side effects Higher Complete Response than currently known competitors, as a single agent Sustained Duration of Response in heavily pre-treated patients Predictable and manageable toxicity Generally well tolerated Predictable, transient and reversible cytopenias Convenience for patients and physicians One-time therapy: 100% patient compliance and superior convenience No repeat visits to cancer centre: improved QoL for patient Optimised healthcare resource utilisation Combination potential Potential synergy from combination with anti-cd20 mabs and others 12

13 Clear opportunity for new, effective and well tolerated therapy for elderly patients who become refractory to rituximab (RTX) Third line, RTX-refractory First line Alkylating agent (cyclophosphamide, bendamustine) + RTX/ anti-cd20 Single agent anti- CD20 Second line Alkylating agent (cyclophosphamide, bendamustine) + RTX/ anti-cd20 Single agent anti- CD20 Betalutin phase 2b PARADIGME population Idelalisib Approved 2014 (FDA, EMA) ORR 66% 1 CR 25% 1 ORR 54% 2 CR 8% 2 mdor 12m 2 Lenalidomide + RTX Lenalidomide + RTX Radioimmunotherapy Copanlisib Approved 2017 (FDA) ORR 59% 3 CR 14% 3 mdor 12m NCCN NHL treatment guidelines Radioimmunotherapy 13 1 Kolstad A, et al. Poster presented at ASH Abstract 2769; 2 Gopal et al, 2014; 3 Dreyling et al., ASH 2017

14 S u r v i v a l Synergistic effect of Betalutin in combination with rituximab in a preclinical NHL model* Survival analysis of nude mice with s.c. Daudi xenografts Betalutin increased binding of rituximab to NHL cells and uptake of rituximab in NHL tumours Strong synergistic effect of combination of Betalutin and rituximab on survival of mice with NHL (Hazard ratio = 0.024, Cox regression) Median survival time in combination: >222 days (p < 0.05) Median survival time with either treatment alone was days with rituximab or 50 days with Betalutin 14 *ASH 2016, Poster version of the Abstract 1489, Repetto-Llamazares et al.

15 ARCHER-1 ready to start as planned In a preclinical model of NHL, the combination of Betalutin and rituximab significantly inhibited tumour growth and prolonged overall survival Phase 2 study in 2L FL Aims to explore preclinical results in clinical phase Enhanced efficacy in combination with rituximab (established standard of care in NHL) Potential foundation for confirmatory phase 3 study in 2L FL 15 *ASH 2016, Poster version of the Abstract 1489, Repetto-Llamazares et al.

16 Maximising the value of Betalutin in NHL Phase 1 study in relapsed/refractory DLBCL ineligible for SCT 10 MBq/kg (+ 60 mg/m 2 llo) N = 3 10 MBq/kg (+100 mg/m 2 llo) N = 3 15 MBq/kg (+ 60 or 100 mg/m 2 llo) N = 3 20 MBq/kg (+ 60 or 100 mg/m 2 llo) N = 3 Phase 1 open label, single administration, ascending dose study Objective: To identify an optimal dosing regimen for Phase 2 Will investigate various Betalutin doses and lilotomab pre-dosing regimens in up to 24 patients llo = lilotomab Day -14: rituximab Study is enrolling in the US and EU 16

17 Solid cash position MNOK 1,200 1, ,018 $ 118M* $ 101M** ** USD/NOK 8.64 ** USD/NOK 7,95 Cash Operating activities Investing & financing activities FX Cash

18 Anticipated key milestones 2H 2017 Betalutin in FL Start* PARADIGME 2H 2017 Betalutin in FL Start ARCHER-1 (Betalutin /rituximab combo in 2L FL) 1H 2018 Humalutin Complete preparation to start clinical study of Humalutin in NHL 2H 2018 Betalutin in DLBCL Prelim data read out of DLBCL Phase 1 study 2H 2019 Betalutin in FL Data read-out/first filing for marketing approval of PARADIGME 18 * Pending approval from regulatory authorities

19 Nordic Nanovector investment proposition Market Leading product Evidence Pipeline Strategy Team Substantial unmet medical need and orphan drug opportunities, a growing NHL market worth over USD 12 billion* First in a new class of Antibody-Radionuclide-Conjugates, designed to deliver better treatment outcomes for NHL patients with a single dose Promising clinical data from Phase 1/2 study indicates the potential for a competitive target product profile Novel targeted therapies with potential to capture further value in NHL and in other B- cell malignancies Well thought-out clinical strategy - unencumbered asset with all options open to maximise shareholder value Management team with extensive industry experience in both development and commercialisation of anticancer drugs 19 *Technavio 2014, Global NHL Therapeutics Market.

20 Nordic Nanovector s mission is to extend and improve the lives of patients with haematological cancers by developing and commercialising innovative Antibody Radionuclide Conjugates (ARC) Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway IR contact: tkvale@nordicnanovector.com